Welcome to our dedicated page for Novaccess Global news (Ticker: XSNX), a resource for investors and traders seeking the latest updates and insights on Novaccess Global stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Novaccess Global's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Novaccess Global's position in the market.
NovAccess Global (OTC PINK:XSNX) has expanded its Advisory Board by appointing Dr. Kim Seroogy, a seasoned neuroscientist with over 30 years of experience in Parkinson's research. Dr. Seroogy leads The Selma Schottenstein Harris Laboratory and has published extensively, receiving funding from prestigious organizations. NovAccess aims to enhance cancer diagnostics and therapeutics, particularly through a novel cancer vaccine targeting brain tumors. This strategic addition is expected to bolster the company's research capabilities and innovation in cancer treatment.
NovAccess Global (OTC PINK:XSNX) announced that Dr. Dwain Irvin was interviewed on MoneyTV on September 11, 2021. MoneyTV, celebrating its 25th year, reaches 200 million homes across 75 countries. Dr. Irvin discussed the company's efforts to gain FDA approval for a Phase IIa Human clinical trial of an immunotherapy targeting brain tumors. NovAccess is advancing a cancer vaccine aimed at enhancing immune responses for patients with glioblastoma multiforme, a serious brain tumor with a limited survival rate.
NovAccess Global (OTC PINK:XSNX) will present at the SBMT 18th World Congress from July 8-11, 2021, in Los Angeles, a notable event focusing on advancements in neuroscience and brain mapping. Dr. Chris Wheeler, co-chairing a presentation on Brain-Immune Interactions and Inflammation on July 9, will highlight the company's progress in cancer therapeutics, particularly targeting glioblastoma multiforme. NovAccess aims to improve treatment options through innovative immunotherapeutic approaches that enhance the patient’s immune response against tumors.
NovAccess Global (OTC PINK:XSNX) received a positive response from the FDA regarding its pre-IND meeting for developing a treatment for glioblastoma multiforme (GBM). The FDA suggested an initial Phase I trial to evaluate product feasibility, toxicity, and activity, while providing guidance on compliance for future trials. They tentatively agreed that further animal studies are unnecessary and accepted the company’s enrollment plan. The global GBM market is projected to reach $1.8 billion by 2027, driven by an increasing geriatric population and the high incidence of brain cancers.
NovAccess Global (OTC PINK:XSNX) has filed its Form 10-K annual filing for FY 2020 and Form 10-Q for the first and second quarters of 2021. The company, focused on developing immunotherapies for brain tumors, is preparing for a pre-IND meeting with the FDA on June 16, 2021, to discuss starting human clinical trials. A recently approved patent protects their novel treatment approach for glioblastoma multiforme, a brain tumor with limited survival rates. CEO Dr. Dwain Irvin asserts that the company is ready to accelerate progress on its promising cancer therapeutic solutions.
NovAccess Global (OTC PINK:XSNX) has secured an unlimited use license to US Patent # 9764014, enhancing its immunotherapy technology against brain tumors. This acquisition, made in September 2020, is pivotal as it positions NovAccess to advance its treatment for glioblastoma multiforme (GBM), a brain tumor with a median survival of less than 15 months. The company plans to file an Investigational New Drug (IND) application with the FDA to initiate human clinical trials, spearheaded by Dr. Chris Wheeler, who brings over 20 years of experience in developing treatments for brain cancer.
NovAccess Global Inc. (OTC PINK:XSNX) enhances its Scientific Advisory Board by adding five distinguished experts in the fields of biotechnology and healthcare. Alongside this, they have appointed Mike Yukich as the new Chief Financial Officer, who brings over 20 years of financial expertise from both public and private sectors. The new advisory board aims to support the company's mission of advancing cancer diagnostics and therapeutics, particularly in improving immune responses in patients with brain tumors, using patented dendritic cell-based immunotherapy.
NovAccess Global (OTC PINK:XSNX) has appointed Dr. Dwain Irvin as CEO, signaling a commitment to advancing biomedical initiatives. Dr. Irvin, a seasoned cancer researcher with a PhD from UCLA, previously led the Biotechnology division at Innovest Global Inc. His extensive background includes research on neural stem cells and immunotherapy for brain tumors. This leadership change is expected to enhance the company's strategic direction and drive its commercial objectives.